Accordion Index: A new tool for the prediction of the efficacy of peg-interferon-α-2b and ribavirin combination therapy for chronic hepatitis C

Hepatology Research

Volumn 38, Issue 3, 2008, Pages 315-318

  Satoh, Takeaki ^a   Masumoto, Akihide ^a  

^a NATIONAL HOSPITAL ORGANIZATION   (Japan)

Author keywords

Accordion Index; Interferon AC ratio; Peg interferon; Ribavirin; Ribavirin AC ratio; Sustained virological response

Indexed keywords

PEGINTERFERON ALPHA2B; RIBAVIRIN; VIRUS RNA;

ACCORDION INDEX; ACCURACY; ADULT; AGED; ARTICLE; CLINICAL ASSESSMENT TOOL; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG EFFICACY; DRUG RESPONSE; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PATIENT CARE PLANNING; PREDICTION; PRIORITY JOURNAL; QUALITY CONTROL; REFERENCE VALUE; RNA ANALYSIS;

EID: 38849171665     PISSN: 13866346     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1872-034X.2007.00272.x     Document Type: Article

References (14)

1. National Institutes of Health. Consensus development conference statement: Management of hepatitis C. Hepatology 2002; 36: S3-20.
2. Manns MP, McHutchison JG, Gordon S et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial. Lancet 2001; 358: 958-65.
3. Fried MW, Shiffman ML, Reddy KR et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-82.
4. Hadziyannis SJ, Sette H, Morgan TR et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: A randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140: 346-55.
5. Zeuzem S, Hultcrantz R, Bourliere M et al. Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3. J Hepatol 2004; 40: 993-9.
6. Mangia A, Santoro R, Minerva N et al. Peginterferon alfa-2b and ribavirin for 12 vs. 24weeks in HCV genotype 2 or 3. N Engl J Med 2005; 352: 2609-17.
7. Davis GL, Wong JB, McHutchison JG et al. Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology 2003; 38: 645-52.
8. Ferenci P, Fried MW, Shiffman ML et al. Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin. J Hepatol 2005; 43: 425-33.
9. Jensen DM, Morgan TR, Marcellin P et al. Early identification of HCV genotype 1 patients responding to 24weeks peginterferon alpha-2a (40 kd)/ ribavirin therapy. Hepatology 2006; 43: 954-60.
10. Berg T, von Wagner M, Nasser S et al. Extended treatment duration for hepatitis C virus type 1: Comparing 48 versus 72weeks of peginterferon-alfa-2a plus ribavirin. Gastroenterology 2006; 131: 451-60.
11. Drusano GL, Preston SL. A 48-week duration of therapy with pegylated interferon alpha 2b plus ribavirin may be too short to maximize long-term response among patients infected with genotype-1 hepatitis C virus. J Infect Dis 2004; 189: 964-70.
12. Lindahl K, Stahle L, Bruchfeld A et al. High-dose ribavirin in combination with standard dose peginterferon for treatment of patients with chronic hepatitis C. Hepatology 2005; 41: 275-9.
13. Lodato F, Azzaroli F, Brillanti S et al. Higher doses of peginterferon alpha-2b administered twice weekly improve sustained virological response in difficult-to-treat patients with chronic hepatitis C: results of a pilot randomized study. J Viral Hepat 2005; 12: 536-42.
14. Hiramatsu N, Oze T, Tsuda N et al. Should aged patients with chronic hepatitis C be treated with interferon and ribavirin combination therapy? Hepatol Res 2006; 35: 185-9.